entertainment -WSS

entertainment

author：leisure time 2025-09-03 03:41:23 - browse：2

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Scientists inch closer to single

focus

WSS

FDA early review: GLP

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

What the airline industry can learn from medicine

Trump indictment: Who are the 'co

No plane should take off without an EpiPen onboard

Gene therapy denied for Afghan refugee whose father aided U.S.

hotspot

entertainment

hotspot

New air purifier tech could be key to improving indoor air quality

Trump indictment: Who are the 'co

After affirmative action ruling, medical educators look to 'holistic review'

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Medical leaders decry Supreme Court decision on affirmative action

Wildfire pollution widens asthma inequities on Long Island

How one medical school became remarkably diverse

Fauci's latest grilling in Congress: 9 hours, behind closed doors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

hotspot

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Mitch McConnell episode has important public health takeaway

Scientists inch closer to single

FDA early review: GLP

Micronoma's microbiome cancer diagnostic approach under fire

Medicare Advantage coverage denials need scrutiny, senators say

hotspot

knowledge

focus

Wikipedia